In this open-label , randomized , phase 2 study , patients with EGFR wild-type and EGFR FISH-positive adenocarcinoma who had developed disease progression after 1 prior platinum-based chemotherapy were randomly assigned ( 1:1 ) to receive erlotinib or pemetrexed until the time of disease progression or death , unacceptable toxicity , or a request for discontinuation by the patient .